Cardiovascular Adverse Events Associated with Ibrutinib in Chronic Lymphocytic Leukemia Patients

被引：0
|
作者：
George, Binsah [1 ]
Thompson, Philip A. [1 ]
Ferrajoli, Alessandria [1 ]
Burger, Jan A. [1 ]
Wierda, William G. [1 ]
O'Brien, Susan M. [1 ]
Durand, Jean-Bernard [2 ]
Keating, Michael J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2015年 / 15卷
关键词：
D O I：
10.1016/j.clml.2015.04.071
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
311
引用
收藏
页码：S208 / S208
页数：1
相关论文
共 50 条
  • [1] Evaluation of Cardiovascular Adverse Events Associated With Ibrutinib, Venetoclax and Idelalisib Used in Treatment of Chronic Lymphocytic Leukemia.
    Mahida, Hetavi
    Gharia, Bharatsinh
    Ugoeke, Nene
    Maludum, Obiora
    Asif, Arif
    Calderon, Dawn
    [J]. CIRCULATION, 2018, 138
  • [2] Incidence and risk factors of bleedingrelated adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
    Wiestner, Adrian
    Lipsky, Andrew
    Farooqui, Mohammed
    Tian, Xin
    Cullinane, Ann
    Nghiem, Khanh
    Lozier, Jay
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 : 163 - 164
  • [3] Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia
    Khountham, Soun
    Shindiapina, Polina
    Mo, Xiaokui
    Lachowiez, Curtis
    Wiczer, Tracy
    Mousa, Luay
    Rogers, Kerry A.
    Andritsos, Leslie A.
    Woyach, Jennifer A.
    Byrd, John C.
    Spurgeon, Stephen E.
    Awan, Farrukh T.
    [J]. LEUKEMIA & LYMPHOMA, 2021, 62 (03) : 716 - 721
  • [4] Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions
    Cho, Hee Jeong
    Baek, Dong Won
    Kim, Juhyung
    Lee, Jung Min
    Moon, Joon Ho
    Sohn, Sang Kyun
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (09) : 819 - 830
  • [5] Ibrutinib-associated cardiovascular adverse events
    [J]. Reactions Weekly, 2019, 1773 (1) : 6 - 6
  • [6] Natural history of non-infectious ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia
    Wiczer, Tracy
    Awan, Farrukh
    Byrd, John C.
    Spurgeon, Stephen
    Jones, Jeffrey
    Woyach, Jennifer
    Andritsos, Leslie
    Rogers, Kerry
    Shindiapina, Polina
    Khountham, Soun
    Levine, Lauren
    Lachowiez, Curtis
    [J]. LEUKEMIA & LYMPHOMA, 2017, 58 : 185 - 186
  • [7] Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
    Lipsky, Andrew H.
    Farooqui, Mohammed Z. H.
    Tian, Xin
    Martyr, Sabrina
    Cullinane, Ann M.
    Nghiem, Khanh
    Sun, Clare
    Valdez, Janet
    Niemann, Carsten U.
    Herman, Sarah E. M.
    Saba, Nakhle
    Soto, Susan
    Marti, Gerald
    Uzel, Gulbu
    Holland, Steve M.
    Lozier, Jay N.
    Wiestner, Adrian
    [J]. HAEMATOLOGICA, 2015, 100 (12) : 1571 - 1578
  • [8] INCREASED RISK OF ADVERSE CARDIOVASCULAR EVENTS ASSOCIATED WITH IBRUTINIB USE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A PROPENSITY-MATCHED POPULATION-BASED COHORT STUDY
    Sabrie, Nasruddin
    Leong, Darryl
    Prica, Anca
    Austin, Peter
    Pang, Andrea
    Fang, Jiming
    Calvillo-Arguelles, Oscar
    Lee, Douglas
    Thavendiranathan, Paaladinesh
    Abdel-Qadir, Husam
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 414 - 414
  • [9] Ibrutinib in Treatment of Patients with chronic lymphocytic Leukemia
    Flammiger, A.
    [J]. ONKOLOGE, 2015, 21 (08): : 732 - 733
  • [10] Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia A systematic review and meta-analysis of randomized trials
    Zhou, Yanhua
    Lu, Hongtao
    Yang, Meifeng
    Xu, Chenhong
    [J]. MEDICINE, 2019, 98 (33)
12345